Characteristics, Treatment Patterns and Survival of International Federation of Gynecology and Obstetrics Stage IV Epithelial Ovarian Cancer-A Population-Based Study.
cancer-directed therapy
ovarian cancer
surgery
survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Nov 2023
30 Nov 2023
Historique:
received:
07
11
2023
revised:
24
11
2023
accepted:
29
11
2023
medline:
9
12
2023
pubmed:
9
12
2023
entrez:
9
12
2023
Statut:
epublish
Résumé
The aim of the present study was to describe an unselected population of patients with diagnosis of FIGO stage IV OC. Data from 1183 patients were available for analysis. The majority of patients (962/1183, 81.3%) received cancer-directed treatment. The median follow-up time was 3.8 years, and the median overall survival duration was 1.9 years. Notably, patients >80 years had a low overall survival rate (HR of age >80 years vs. ≤50 years was 3.81, 95%-CI [2.76, 5.27], In this cohort of patients with FIGO stage IV OC, more than 80% of the patients received cancer-directed treatment. Age and high-grade serous histology were determinants for survival. The highest overall survival rate was observed in patients who underwent surgery followed by systemic treatment.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of the present study was to describe an unselected population of patients with diagnosis of FIGO stage IV OC.
METHODS
METHODS
Data from 1183 patients were available for analysis.
RESULTS
RESULTS
The majority of patients (962/1183, 81.3%) received cancer-directed treatment. The median follow-up time was 3.8 years, and the median overall survival duration was 1.9 years. Notably, patients >80 years had a low overall survival rate (HR of age >80 years vs. ≤50 years was 3.81, 95%-CI [2.76, 5.27],
CONCLUSIONS
CONCLUSIONS
In this cohort of patients with FIGO stage IV OC, more than 80% of the patients received cancer-directed treatment. Age and high-grade serous histology were determinants for survival. The highest overall survival rate was observed in patients who underwent surgery followed by systemic treatment.
Identifiants
pubmed: 38067378
pii: cancers15235676
doi: 10.3390/cancers15235676
pmc: PMC10705193
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ann Oncol. 2019 May 1;30(5):672-705
pubmed: 31046081
J Clin Med. 2021 Oct 21;10(21):
pubmed: 34768353
Cancers (Basel). 2023 Oct 22;15(20):
pubmed: 37894466
N Engl J Med. 2010 Sep 2;363(10):943-53
pubmed: 20818904
Gynecol Oncol. 2017 Feb;144(2):266-273
pubmed: 27916269
Gynecol Oncol. 1999 Mar;72(3):278-87
pubmed: 10053096
JAMA Oncol. 2017 Jan 01;3(1):76-82
pubmed: 27892998
Gynecol Oncol. 2020 Jun;157(3):593-598
pubmed: 32171566
Gynecol Oncol. 2013 Sep;130(3):493-8
pubmed: 23747291
Gynecol Oncol. 2010 Oct;119(1):38-42
pubmed: 20609464
J Transl Med. 2020 Mar 23;18(1):134
pubmed: 32293460
Ann Surg Oncol. 2012 Mar;19(3):959-65
pubmed: 21994038
Gynecol Oncol. 2023 Mar;170:46-53
pubmed: 36621269
J Clin Oncol. 2002 Mar 1;20(5):1248-59
pubmed: 11870167
Gynecol Oncol. 2016 Sep;142(3):597-607
pubmed: 27335253
Eur J Cancer. 2016 Sep;64:22-31
pubmed: 27323348
Gynecol Oncol. 2012 Jun;125(3):649-54
pubmed: 22370602
Gynecol Oncol. 2021 Apr;161(1):244-250
pubmed: 33581846
Acta Obstet Gynecol Scand. 2022 Mar;101(3):334-343
pubmed: 35187660
Gynecol Oncol. 2016 Feb;140(2):215-20
pubmed: 26691222
Int J Gynecol Cancer. 2019 Jul;29(6):1032-1037
pubmed: 31263022
Gynecol Oncol. 2020 Apr;157(1):209-213
pubmed: 31952843
BMC Cancer. 2015 Aug 13;15:583
pubmed: 26268818
Gynecol Oncol. 2017 Aug;146(2):273-278
pubmed: 28549816
PLoS One. 2012;7(7):e39415
pubmed: 22844394
Eur J Surg Oncol. 2020 May;46(5):868-875
pubmed: 31818526
JAMA Oncol. 2021 Dec 01;7(12):1782-1790
pubmed: 34591081
Int J Gynecol Cancer. 2017 Jan;27(1):28-36
pubmed: 27870700
Gynecol Oncol. 2016 Jul;142(1):30-37
pubmed: 27107721